EyePoint Pharmaceuticals appoints new chairman of the board: 3 key details

EyePoint Pharmaceuticals selected Göran Ando, MD, as its next chairman of the board.

Advertisement

Here are the key details to know:

1. David J. Mazzo, PhD, is stepping down as non-executive chairman and will remain on the board to serve as the chair of the compensation committee.

2. Dr. Ando was appointed to the EyePoint board of directors in June 2018. He previously served as Novo Nordisk’s chairman of the board. He currently serves as a EW Healthcare Partners’ senior advisor.

3. Dr. Ando began his career at Pfizer where he held several senior clinical positions in the U.S. and Europe.

More articles on supply chain:
Baxter’s bone graft substitute approved for orthopedic procedures — 5 facts
3 Ways to cut operating room inventory in an ASC
ASC supply chain tip of the day: Reduce waste

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply chain

Advertisement

Comments are closed.